A Phase 3 interventional study of Rituximab and Anti-inflammatory drugs in Rheumatoid Arthritis, sponsored by Genentech, Inc.. Completed. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-04-17.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies testing rituximab in Arthritis, Rheumatoid — 5 open to participants now, 6 under way, 1 of them phase 3. Rituximab · Arthritis, Rheumatoid.
Among the 63 studies testing rituximab in Arthritis, Rheumatoid, this one is the 3rd largest by enrollment, is one of 11 that started in 2007, is one of 27 in phase 3, and was the 12th registered.
3,337 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.
Browse Arthritis, Rheumatoid studies →5 of the 63 studies testing rituximab in Arthritis, Rheumatoid are open now, in 4 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University Hospital, Strasbourg, France · Sites in France
Ages 18+
Universitaire Ziekenhuizen KU Leuven · Sites in Belgium
Ages 18+
University of Nebraska · Sites in United States
Ages 19+
Chinese SLE Treatment And Research Group · Sites in China
Ages 18–80
By country, each count listing its studies:
Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 13 · Phase 3 27 · Phase 4 14
First in 2001; this study’s year is marked. 11 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 578 is above the median of 96 across 2,224 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 159 across the 63 interventional studies. Of the 57 that completed or were terminated, 37 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 63 have an industry lead sponsor. The 10 most frequent:
This study is registered under Genentech, Inc., one of the names counted as Hoffmann-La Roche. Under that name alone:
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche: 2 open now, 2 under way, none of them phase 3. Of 214 finished, 139 (65%) have results posted.
Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 19th largest by enrollment of the 141 interventional ones that give a count, is one of 15 that started in 2007, is one of 85 in phase 3, and was the 29th registered.
Hoffmann-La Roche’s Arthritis, Rheumatoid studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 63 studies testing rituximab in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 219 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase III, open-label study of a total of approximately 560 subjects with active rheumatoid arthritis (RA) who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Enrollment in the study was conducted in two stages. In Stage I of the study, approximately 400 subjects receiving non-biological DMARDs (with the exception of methotrexate [MTX] monotherapy or MTX and leflunomide combination therapy) were enrolled. In Stage II of the study, approximately 160 subjects receiving a Federal Drug Administration-approved biological DMARD at the time of screening were enrolled.
Inclusion Criteria (Stage I):
Exclusion Criteria (Stage I):
Inclusion Criteria (Stage II):
Exclusion Criteria (Stage II):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stage I patients received 2 doses of rituximab 1000 mg administered intravenously (IV) 14 days apart at the beginning of the study (Days 1 and 15). During Weeks 24 to 40, patients who met disease activity and safety criteria were eligible to receive 2 additional IV infusions of rituximab 1000 mg given 14 days apart. Concomitant non-biological disease-modifying anti-rheumatic drug (DMARD) therapy, at a stable dose and route, was continued during the study, except for protocol defined prohibited DMARDs/combinations.
Drug: Rituximab · Drug: Anti-inflammatory drugs
Stage II patients received 2 doses of rituximab 500 mg administered intravenously (IV) 14 days apart at the beginning of the study (Days 1 and 15). During Weeks 24 to 40, patients who met disease activity and safety criteria were eligible to receive 2 additional IV infusions of rituximab 500 mg given 14 days apart. Concomitant biological and non-biological disease-modifying anti-rheumatic drug (DMARD) therapy, at a stable dose and route, was continued during the study, except for protocol defined prohibited DMARDs/combinations.
Drug: Rituximab · Drug: Anti-inflammatory drugs
Rituximab was supplied as a concentrate for IV administration at a concentration of 10 mg/mL in 500 mg (50 mL) single-use vials.
Each rituximab infusion was preceded by methylprednisolone 100 mg IV. Use of stable doses of oral corticosteroids was permitted (≤ 10 mg of prednisone or equivalent per day) as were stable doses of nonsteroidal anti-inflammatory drugs (NSAIDs).
Percentage of Patients Developing a Serious Adverse Event (SAE) Within 24 Weeks After Receiving the First Course of Rituximab Treatment
An adverse event (AE) is any unfavorable and unintended sign, symptom, significantly abnormal laboratory finding, or disease temporally associated with the use of an investigational medical product or other protocol-imposed intervention. An AE was classified as an SAE if it: Resulted in death, persistent or significant disability/incapacity, or congenital anomaly/birth defect in a neonate/infant born to a mother exposed to the investigational product; required or prolonged inpatient hospitalization; was life-threatening or considered a significant medical event by the investigator.
Time frame: From first treatment with rituximab (Day 1) through Week 24
Percentage of Patients Who Developed a Serious Adverse Event (SAE) During or Within 24 Hours of Rituximab Infusions
The percentage of patients developing a SAE during or within 24 hours of a rituximab infusion is reported separately for each of the 2 infusions in the first course of treatment (Days 1 and 15) and the second course of treatment (optional retreatment during Weeks 24 to 40). See the Primary Outcome Measure for a definition of a SAE.
Time frame: From start of rituximab treatment through 24 hours
Percentage of Patients Who Developed a Serious Adverse Event (SAE) Within 24 Weeks After Receiving the Second Course (Optional Retreatment) of Rituximab Treatment
An adverse event (AE) is any unfavorable and unintended sign, symptom, significantly abnormal laboratory finding, or disease temporally associated with the use of an investigational medical product or other protocol-imposed intervention. An AE was classified as an SAE if it: Resulted in death, persistent or significant disability/incapacity, or congenital anomaly/birth defect in a neonate/infant born to a mother exposed to the investigational product; required or prolonged inpatient hospitalization; was life-threatening or considered a significant medical event by the investigator.
Time frame: From start of the second course of rituximab treatment through Week 48
Percentage of Patients With an Improvement of 20%, 50%, and 70% in American College of Rheumatology (ACR) Scores (ACR20/50/70) From Baseline at Weeks 24 and 48
Improvement must be seen in tender and swollen joint counts and in at least 3 of the following 5 parameters. Patient and physician assessment of patient disease activity (DA) in previous 24 hours on a visual analog scale (VAS, no DA to maximum DA); patient assessment of pain in previous 24 hours on a VAS (none to unbearable); Health Assessment Questionnaire-Disability Index (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do); and C reactive protein or, if missing, erythrocyte sedimentation rate.
Time frame: Baseline to Week 24 and Week 48
Percentage of Patients Achieving Disease Activity Score 28-Erythrocyte Sedimentation Rate (DAS 28-ESR) Remission and DAS 28-ESR Low Disease Activity Scores at Weeks 24 and 48
DAS 28-ESR was calculated using counts of tender and swollen joints (28 joints, 28TJC and 28SJC), a patient assessment (PA) of disease activity (DA) in previous 24 hours on a visual analog scale (no DA to maximum DA), and ESR at the current visit, using the following formula: 0.56 × 28TJC + 0.28 × 28SJC + 0.70 × ln(ESR) + 0.014 × PADA. The DAS 28-ESR score ranges from 0 to 10, with higher scores indicating more rheumatoid arthritis. DAS28-ESR Remission was defined as a DAS 28-ESR score of \< 2.6. DAS28-ESR Low Disease Activity was defined as a DAS28-ESR score of ≤ 3.2.
Time frame: Week 24 and Week 48
Percentage of Patients With European League Against Rheumatism (EULAR) Good and Moderate Responses at Weeks 24 and 48
Improvement in the post-baseline DAS 28-ESR score from baseline was used to determine the EULAR responses of moderate response and good response. The DAS 28-ESR score ranges from 0 to 10, with higher scores indicating more rheumatoid arthritis. For a post-baseline score ≤ 3.2, an improvement \> 0.6 to ≤ 1.2 was a moderate response and ≥ 1.2 a good response. For a post-baseline score \> 3.2 to ≤ 5.1, an improvement \> 0.6 was a moderate response. For a post-baseline score \> 5.1, an improvement ≥ 1.2 was a moderate response. A good response could not be achieved for post-baseline scores \> 3.2.
Time frame: Baseline to Week 24 and Week 48
Health Assessment Questionnaire-Disability Index (HAQ-DI) Change From Baseline at Weeks 24 and 48
The HAQ-DI assesses how well the patient is able to perform 8 activities: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. The patient answers 20 questions with 1 of 4 responses with the past week as the time frame: 0=without difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. The highest score for any question in a category determines the category score. The total score ranges from 0 (no disability) to 3 (completely disabled). A negative change score indicates improvement.
Time frame: Baseline to Week 24 and Week 48
The study was conducted in 2 stages. Stage I: Patients with an inadequate response to non-biological disease-modifying antirheumatic drugs (DMARDS) were treated with rituximab 1000 mg. Stage II: Patients with an inadequate response to a biological DMARD were treated with rituximab 500 mg. Both groups continued to receive DMARDs.
| Milestone | Rituximab 1000 mg (Stage I Patients) | Rituximab 500 mg (Stage II Patients) |
|---|---|---|
| Started | 401 | 176 |
| Week 24 | 376 | 160 |
| Week 48 | 338 | 134 |
| Completed | 306 | 118 |
| Not completed | 95 | 58 |
| Withdrew: Death | 1 | 5 |
| Withdrew: Adverse event | 5 | 6 |
| Withdrew: Lost to follow-up | 18 | 12 |
| Withdrew: Patient's/guardian's decision | 58 | 30 |
| Withdrew: Physician decision | 13 | 4 |
| Withdrew: Pregnancy | 0 | 1 |
An adverse event (AE) is any unfavorable and unintended sign, symptom, significantly abnormal laboratory finding, or disease temporally associated with the use of an investigational medical product or other protocol-imposed intervention. An AE was classified as an SAE if it: Resulted in death, persistent or significant disability/incapacity, or congenital anomaly/birth defect in a neonate/infant born to a mother exposed to the investigational product; required or prolonged inpatient hospitalization; was life-threatening or considered a significant medical event by the investigator.
| Percentage of participants | Rituximab 1000 mg (Stage I Patients) | Rituximab 500 mg (Stage II Patients) |
|---|---|---|
| Percentage of Patients Developing a Serious Adverse Event (SAE) Within 24 Weeks After Receiving the First Course of Rituximab Treatment | 6.0 | 9.1 |
The percentage of patients developing a SAE during or within 24 hours of a rituximab infusion is reported separately for each of the 2 infusions in the first course of treatment (Days 1 and 15) and the second course of treatment (optional retreatment during Weeks 24 to 40). See the Primary Outcome Measure for a definition of a SAE.
| Percentage of participants | Rituximab 1000 mg (Stage I Patients) | Rituximab 500 mg (Stage II Patients) |
|---|---|---|
| 1st infusion, 1st course of treatment | 0.2 | 0.0 |
| 2nd infusion, 1st course of treatment | 0.0 | 0.0 |
| 1st infusion, 2nd course of treatment | 0.0 | 0.0 |
| 2nd infusion, 2nd course of treatment | 0.0 | 0.0 |
An adverse event (AE) is any unfavorable and unintended sign, symptom, significantly abnormal laboratory finding, or disease temporally associated with the use of an investigational medical product or other protocol-imposed intervention. An AE was classified as an SAE if it: Resulted in death, persistent or significant disability/incapacity, or congenital anomaly/birth defect in a neonate/infant born to a mother exposed to the investigational product; required or prolonged inpatient hospitalization; was life-threatening or considered a significant medical event by the investigator.
| Percentage of participants | Rituximab 1000 mg (Stage I Patients) | Rituximab 500 mg (Stage II Patients) |
|---|---|---|
| Percentage of Patients Who Developed a Serious Adverse Event (SAE) Within 24 Weeks After Receiving the Second Course (Optional Retreatment) of Rituximab Treatment | 7.2 | 6.1 |
Improvement must be seen in tender and swollen joint counts and in at least 3 of the following 5 parameters. Patient and physician assessment of patient disease activity (DA) in previous 24 hours on a visual analog scale (VAS, no DA to maximum DA); patient assessment of pain in previous 24 hours on a VAS (none to unbearable); Health Assessment Questionnaire-Disability Index (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do); and C reactive protein or, if missing, erythrocyte sedimentation rate.
| Percentage of participants | Rituximab 1000 mg (Stage I Patients) | Rituximab 500 mg (Stage II Patients) |
|---|---|---|
| ACR20 at Week 24 | 36.9 | 30.7 |
| ACR50 at Week 24 | 15.7 | 10.2 |
| ACR70 at Week 24 | 7.7 | 5.1 |
| ACR20 at Week 48 | 50.6 | 48.9 |
| ACR50 at Week 48 | 25.9 | 22.7 |
| ACR70 at Week 48 | 11.0 | 9.1 |
DAS 28-ESR was calculated using counts of tender and swollen joints (28 joints, 28TJC and 28SJC), a patient assessment (PA) of disease activity (DA) in previous 24 hours on a visual analog scale (no DA to maximum DA), and ESR at the current visit, using the following formula: 0.56 × 28TJC + 0.28 × 28SJC + 0.70 × ln(ESR) + 0.014 × PADA. The DAS 28-ESR score ranges from 0 to 10, with higher scores indicating more rheumatoid arthritis. DAS28-ESR Remission was defined as a DAS 28-ESR score of \< 2.6. DAS28-ESR Low Disease Activity was defined as a DAS28-ESR score of ≤ 3.2.
| Percentage of participants | Rituximab 1000 mg (Stage I Patients) | Rituximab 500 mg (Stage II Patients) |
|---|---|---|
| DAS 28-ESR Remission at Week 24 (n=391, 171) | 8.4 | 6.4 |
| DAS 28-ESR Low DA at Week 24 (n=391, 171) | 15.6 | 11.7 |
| DAS 28-ESR Remission at Week 48 (n=389, 172) | 12.6 | 7.0 |
| DAS 28-ESR Low DA at Week 48 (n=389, 172) | 23.4 | 22.1 |
Improvement in the post-baseline DAS 28-ESR score from baseline was used to determine the EULAR responses of moderate response and good response. The DAS 28-ESR score ranges from 0 to 10, with higher scores indicating more rheumatoid arthritis. For a post-baseline score ≤ 3.2, an improvement \> 0.6 to ≤ 1.2 was a moderate response and ≥ 1.2 a good response. For a post-baseline score \> 3.2 to ≤ 5.1, an improvement \> 0.6 was a moderate response. For a post-baseline score \> 5.1, an improvement ≥ 1.2 was a moderate response. A good response could not be achieved for post-baseline scores \> 3.2.
| Percentage of participants | Rituximab 1000 mg (Stage I Patients) | Rituximab 500 mg (Stage II Patients) |
|---|---|---|
| Good EULAR Response at Week 24 | 13.7 | 9.1 |
| Moderate EULAR Response at Week 24 | 39.2 | 34.1 |
| Good EULAR Response at Week 48 | 21.2 | 18.2 |
| Moderate EULAR Response at Week 48 | 44.1 | 43.8 |
The HAQ-DI assesses how well the patient is able to perform 8 activities: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. The patient answers 20 questions with 1 of 4 responses with the past week as the time frame: 0=without difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. The highest score for any question in a category determines the category score. The total score ranges from 0 (no disability) to 3 (completely disabled). A negative change score indicates improvement.
| Units on a scale | Rituximab 1000 mg (Stage I Patients) | Rituximab 500 mg (Stage II Patients) |
|---|---|---|
| Week 24 | -0.28 ± 0.474 | -0.28 ± 0.495 |
| Week 48 | -0.33 ± 0.508 | -0.32 ± 0.512 |
Collected over Adverse events (AE) were recorded from the time when informed consent was obtained until Week 48, Week 4 of the safety follow-up (SFU) period, or early discontinuation. Beyond Week 4 of the SFU period, only serious or infectious AEs were recorded.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rituximab 1000 mg (Stage I Patients) | — | 48/401 (12%) | 278/401 (69.3%) |
| Rituximab 500 mg (Stage II Patients) | — | 27/176 (15.3%) | 128/176 (72.7%) |
| Event | Rituximab 1000 mg (Stage I Patients) | Rituximab 500 mg (Stage II Patients) |
|---|---|---|
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 2/401 | 3/176 |
| Ulna fractureInjury, poisoning and procedural complications | 0/401 | 2/176 |
| Chest painGeneral disorders | 4/401 | 1/176 |
| PneumoniaInfections and infestations | 4/401 | 1/176 |
| CellulitisInfections and infestations | 4/401 | 1/176 |
| BronchitisInfections and infestations | 1/401 | 1/176 |
| Septic shockInfections and infestations | 0/401 | 1/176 |
| Lumbar spinal stenosisMusculoskeletal and connective tissue disorders | 2/401 | 1/176 |
| ArthritisMusculoskeletal and connective tissue disorders | 0/401 | 1/176 |
| PericarditisCardiac disorders | 1/401 | 1/176 |
| Event | Rituximab 1000 mg (Stage I Patients) | Rituximab 500 mg (Stage II Patients) |
|---|---|---|
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 50/401 | 28/176 |
| Upper respiratory tract infectionInfections and infestations | 51/401 | 27/176 |
| HeadacheNervous system disorders | 38/401 | 25/176 |
| SinusitisInfections and infestations | 45/401 | 23/176 |
| NauseaGastrointestinal disorders | 31/401 | 22/176 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 47/401 | 12/176 |
| Urinary tract infectionInfections and infestations | 45/401 | 15/176 |
| CoughRespiratory, thoracic and mediastinal disorders | 36/401 | 10/176 |
| BronchitisInfections and infestations | 35/401 | 12/176 |
| HypertensionVascular disorders | 28/401 | 14/176 |
| Age, Customized(Participants) | Rituximab 1000 mg (Stage I Patients) | Rituximab 500 mg (Stage II Patients) | Total |
|---|---|---|---|
| 18 - 25 years | 8 | 5 | 13 |
| 26 - 35 years | 22 | 8 | 30 |
| 36 - 45 years | 59 | 26 | 85 |
| 46 - 55 years | 132 | 48 | 180 |
| 56 - 65 years | 133 | 67 | 200 |
| 66 - 75 years | 38 | 19 | 57 |
| 76 - 85 years | 9 | 3 | 12 |
| > 85 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Rituximab 1000 mg (Stage I Patients) | Rituximab 500 mg (Stage II Patients) | Total |
|---|---|---|---|
| Female | 302 | 154 | 456 |
| Male | 99 | 22 | 121 |
No study locations are listed for this record.
The record gives a start of Jan 2007, a primary completion of May 2011 and a completion of Feb 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2012, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rituximab